Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
1. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis of a knee.
2. The method of claim 1 , wherein the human being experiences pain relief at three months after the denosumab is first administered.
3. The method of claim 1 , wherein about 30 mg to about 180 mg of denosumab is administered to the human being no more than once a week.
4. The method of claim 1 , wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.
5. The method of claim 1 , further comprising administration of an analgesic or an anti-inflammatory agent.
6. The method of claim 5 , wherein the analgesic agent is a narcotic pain reliever, an opioid pain reliever, a steroid, acetaminophen, morphine, codeine, fentanyl, oxycodone, hydrocodone, hydromorphone, triamcinolone, prednisone, methylprednisolone, or cortisone.
7. The method of claim 1 , wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab.
8. The method of claim 1 , wherein the denosumab is administered by injection.
9. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis affecting a hip.
10. The method of claim 9 , wherein the human being experiences pain relief at three months after the denosumab is first administered.
11. The method of claim 9 , wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the human being within a four week period.
12. The method of claim 9 , wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.
13. The method of claim 9 , further comprising administration of an analgesic or an anti-inflammatory agent.
14. The method of claim 13 , wherein the anti-inflammatory agent is an nonsterioidal anti-inflammatory drug (NSAID), ibuprofen, naproxen, ketoprofen, celecoxib, firocoxib, or meloxicam.
15. The method of claim 9 , wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab.
16. The method of claim 9 , wherein the denosumab is administered by injection.
17. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis affecting an elbow, a wrist, or a finger.
18. The method of claim 17 , wherein the human being experiences pain relief at three months after the denosumab is first administered.
19. The method of claim 17 , wherein about 0.5 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a three to five week period.
20. The method of claim 17 , wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.
21. The method of claim 17 , further comprising administration of an analgesic or an anti-inflammatory agent.
22. The method of claim 17 , wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab.
23. The method of claim 17 , wherein the denosumab is administered by injection.
24. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis affecting a shoulder.
25. The method of claim 24 , wherein the human being experiences pain relief at three months after the denosumab is first administered.
26. The method of claim 24 , wherein about 30 mg to about 150 mg of denosumab is administered to the human being no more than once a week.
27. The method of claim 24 , wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.
28. The method of claim 24 , further comprising administration of an analgesic or an anti-inflammatory agent.
29. The method of claim 24 , wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab.
30. The method of claim 24 , wherein the denosumab is parenterally administered.